The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study

References

• Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. J Am Med Assoc 2006;295:2164–7
   PubMed Web of Science ®Google Scholar
• Leenhardt L, Grosclaude P, Cherie-Challine L. Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004;14:1056–60
   PubMedGoogle Scholar
• Hughes DT, Haymart MR, Miller BS, et al. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid 2011;21:231–6
   Google Scholar
• Neuhold N, Schultheis A, Hermann M, et al. Incidental papillary microcarcinoma of the thyroid – further evidence of a very low malignant potential: a retrospective clinicopathological study with up to 30 years of follow-up. Ann Surg Oncol 2011;18:3430–6
   Google Scholar
• Page C, Biet A, Boute P, et al. ‘Aggressive papillary’ thyroid microcarcinoma. Eur Arch Otorhinolaryngol 2009;266:1959–63
   Google Scholar
• MacCorkle RA, Tan T-H. Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys 2005;43:451–61
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742–62
   PubMed Web of Science ®Google Scholar
• Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007;148:936–41
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008;8:83–95
   PubMed Web of Science ®Google Scholar
• Kim SK, Kim D-L, Han HS, et al. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 2008;17:118–25
   PubMed Web of Science ®Google Scholar
• Fugazzola L, Puxeddu E, Avenia N, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006;13:455–64
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949–54
   PubMed Web of Science ®Google Scholar
• Finkelstein A, Levy GH, Hui P, et al. Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology 2012;60:1052–9
   Google Scholar
• Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol 2004;61:239–43
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee E-S, Kim Y-S. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007;110:38–46
   PubMed Web of Science ®Google Scholar
• Li C, Lee KC, Schneider EB, et al. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 2012;97:4559–70
   PubMed Web of Science ®Google Scholar
• Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013;309:1493–501
   PubMed Web of Science ®Google Scholar
• Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol 2006;65:364–8
   PubMed Web of Science ®Google Scholar
• Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373–9
   PubMed Web of Science ®Google Scholar
• Paterson IC, Greenlee R, Adams Jones D. Thyroid cancer in Wales 1985–1996: a cancer registry-based study. Clin Oncol (R Coll Radiol) 1999;11:245–51
   Google Scholar
• LiVolsi VA, Fadda G, Baloch ZW. Prognostic factors in well-differentiated thyroid cancer. Rays 2000;25:163–75
   Google Scholar
• Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998;83:1012–21
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Baudin E, Travagli JP. Papillary and follicular cancer of the thyroid. Cancers papillaire et vesiculaire de la thyroide 1998;27:1479–81
   Google Scholar
• Ranjbari N, Almasi S, Mohammadi-Asl J, et al. BRAF mutations in Iranian patients with papillary thyroid carcinoma. Asian Pac J Cancer Prev 2013;14:2521–3
   Google Scholar
• Puxeddu E, Moretti S. Clinical prognosis in BRAF-Mutated PTC. Arq Bras Endocrinol Metabol 2007;51:736–47
   PubMedGoogle Scholar
• Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63:4561–7
   PubMed Web of Science ®Google Scholar
• Kumagai A, Namba H, Saenko VA, et al. Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 2004;89:4280–4
   PubMedGoogle Scholar
• Penko K, Livezey J, Fenton C, et al. BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 2005;15:320–5
   PubMedGoogle Scholar
• D’Avanzo A, Ituarte P, Treseler P, et al. Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Thyroid 2004;14:453–8
   PubMed Web of Science ®Google Scholar
• Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008;93:3943–9
   PubMed Web of Science ®Google Scholar
• Voutilainen PE, Siironen P, Franssila KO, et al. AMES, MACIS and TNM prognostic classifications in papillary thyroid carcinoma. Anticancer Res 2003;23:4283–8
   PubMed Web of Science ®Google Scholar
• Cushing SL, Palme CE, Audet N, et al. Prognostic factors in well-differentiated thyroid carcinoma. Laryngoscope 2004;114:2110–5
   Google Scholar
• Elisei R, Molinaro E, Agate L, et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab 2010;95:1516–27
   PubMedGoogle Scholar
• Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:4085–90
   PubMed Web of Science ®Google Scholar
• Lima J, Trovisco V, Soares P, et al. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 2004;89:4267–71
   PubMed Web of Science ®Google Scholar
• Hamatani K, Eguchi H, Ito R, et al. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res 2008;68:7176–82
   PubMed Web of Science ®Google Scholar
• Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007;246; 466–470; discussion 470–61
   PubMed Web of Science ®Google Scholar